{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:07:00Z","timestamp":1784567220751,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.imlet.2026.107199","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:33:38Z","timestamp":1780727618000},"page":"107199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Precise sequential combination of cisplatin and cyclophosphamide induces higher anti-tumor and immunomodulatory effects against experimental Ehrlich ascites"],"prefix":"10.1016","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-4399","authenticated-orcid":false,"given":"Mohmed Labib","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaila M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaimaa Talat","family":"El shahry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shymaa Sobhy","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2026.107199_bib0001","first-page":"41","article-title":"Immunomedulatory effects of single and combinatorial anti-cancer chemotherapy in a tumor mouse model","volume":"1","author":"Salem","year":"2014","journal-title":"Egypt J. Exp. Biol."},{"key":"10.1016\/j.imlet.2026.107199_bib0002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2019.04.017","article-title":"Emerging strategies in cancer therapy combining chemotherapy with immunotherapy","volume":"454","author":"Luo","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.imlet.2026.107199_bib0003","first-page":"721","article-title":"Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells","volume":"58","author":"Salem","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2026.107199_bib0004","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.imlet.2026.107199_bib0005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.imlet.2026.107199_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-025-02641-4","article-title":"Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies","volume":"42","author":"Shah","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.imlet.2026.107199_bib0007","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.imlet.2026.107199_bib0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.imlet.2026.107199_bib0009","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.imlet.2026.107199_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.imlet.2026.107199_bib0011","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imlet.2026.107199_bib0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin\u2013cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2026.107199_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2527303","article-title":"Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy","volume":"14","author":"Gbadamosi","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imlet.2026.107199_bib0014","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2020.01590","article-title":"Myeloid cells as clinical biomarkers for immune checkpoint blockade","volume":"11","author":"Peranzoni","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.imlet.2026.107199_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells","volume":"13","author":"S\u00e1nchez-Le\u00f3n","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1134\/S1547477124702601","article-title":"Modifying effect of 1-\u03b2-d-arabinofuranosylcytosine on the growth of the solid tumor Ehrlich carcinoma in mice under in vivo and ex vivo proton irradiation of cells","volume":"22","author":"Belyakova","year":"2025","journal-title":"Phys. Part. Nucl. Lett."},{"key":"10.1016\/j.imlet.2026.107199_bib0019","article-title":"Ehrlich ascites carcinoma mice model for studying liver inflammation and fibrosis","volume":"4","author":"Gowda","year":"2022","journal-title":"Adv. Cancer Biol."},{"key":"10.1016\/j.imlet.2026.107199_bib0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cellimm.2012.03.010","article-title":"Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide","volume":"276","author":"Salem","year":"2012","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0021","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.954471","article-title":"Chemotherapy-induced myeloid suppressor cells and antitumor immunity: the Janus face of chemotherapy in immunomodulation","volume":"3","author":"Ding","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imlet.2026.107199_bib0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nri3671","article-title":"Monocytes and macrophages: developmental pathways and tissue homeostasis","volume":"14","author":"Ginhoux","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0023","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.coi.2010.01.020","article-title":"Adoptive T cell therapy of cancer","volume":"22","author":"Brenner","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.imlet.2026.107199_bib0024","series-title":"Progress in Nucleic Acid Research and Molecular Biology","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","article-title":"Cisplatin: From DNA damage to cancer chemotherapy","volume":"67","author":"Cohen","year":"2001"},{"key":"10.1016\/j.imlet.2026.107199_bib0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2026.107199_bib0026","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.imlet.2026.107199_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2026.107199_bib0028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol. Oncol."},{"key":"10.1016\/j.imlet.2026.107199_bib0029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2026.107199_bib0030","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.imlet.2026.107199_bib0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.imlet.2026.107199_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1116016","article-title":"Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment","volume":"13","author":"Cao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2026.107199_bib0033","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1935557","article-title":"Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients","volume":"10","author":"Van Wigcheren","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imlet.2026.107199_bib0034","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/cancers3033114","article-title":"Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines","volume":"3","author":"Weir","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.imlet.2026.107199_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108111","article-title":"The immune modifying effects of chemotherapy and advances in chemo-immunotherapy","volume":"236","author":"Principe","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.imlet.2026.107199_bib0036","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.imlet.2026.107199_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/JLB.3MR0717-292R","article-title":"Roles of neutrophils in cancer growth and progression","volume":"103","author":"Galdiero","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.imlet.2026.107199_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101225","article-title":"Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy","volume":"39","author":"Xiong","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.imlet.2026.107199_bib0039","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/pharmaceutics12030256","article-title":"Dendritic cells and immunogenic cancer cell death: a combination for improving antitumor immunity","volume":"12","author":"Lamberti","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.imlet.2026.107199_bib0040","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/annonc\/mdx503","article-title":"Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?","volume":"28","author":"Sahin","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.imlet.2026.107199_bib0041","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Inflammatory and immune reactions in response to chemotherapy-induced cell death","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.imlet.2026.107199_bib0042","volume":"909","author":"Yang","year":"2016"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:43:29Z","timestamp":1784565809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0165247826000726"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107199","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precise sequential combination of cisplatin and cyclophosphamide induces higher anti-tumor and immunomodulatory effects against experimental Ehrlich ascites","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Immunological Societies. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107199"}}